NCT04354389View on ClinicalTrials.gov

DAS181 for STOP COVID-19

PHASE2/PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 25, 2020

Primary Completion Date

September 30, 2020

Study Completion Date

November 30, 2020

Conditions
COVID-19
Interventions
DRUG

DAS181

4.5 mg b.i.d

DRUG

Placebo

q.d. or b.i.d.

DRUG

DAS181

4.5 mg q.d.

Trial Locations (2)

Unknown

Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan

A.O.U Policlinico Di Modena, Modena

Sponsors
All Listed Sponsors
lead

Ansun Biopharma, Inc.

INDUSTRY

NCT04354389 - DAS181 for STOP COVID-19 | Biotech Hunter | Biotech Hunter